Skip to main content
TipRanks
Go Ultimate75% OFF

David Andrew Posner Insider Profile

4 Followers

David Andrew Posner, Director at Pharmadrug, holds 8.30M shares in High Fusion Inc. (Ticker: TSE:MJMJ), holds 1.80M shares in Pharmadrug (Ticker: TSE:PHRX), holds 1.26M shares in Beckett's (Ticker: BKTSF).

David Andrew Posner's Trading History

MJMJ
High Fusion Inc.
Jul 06, 2019―Uninformative Sell40.00KC$83.03K
PHRX
Pharmadrug
Jun 20, 2019DirectorInformative Buy39.00KC$18.00K
STHZF
StateHouse Holdings
Dec 06, 2018DirectorUninformative Sell41.50K$20.96K
SATO
SATO Technologies
Mar 24, 2017DirectorInformative Buy5.00KC$3.93K
BKTSF
Beckett's
―Director―$12.63K

You May Also Like

David Andrew Posner insider profile FAQ

What is the percentage of profitable transactions made by David Andrew Posner?
The percentage of profitable transactions made by David Andrew Posner is 14%.
What is the average return per transaction made by David Andrew Posner?
The average return per transaction made by David Andrew Posner is -44.70%.
What stocks does David Andrew Posner hold?
David Andrew Posner holds: TSE:PHRX, TSE:MJMJ, BKTSF, STHZF, TSE:SATO stocks.
What was David Andrew Posner’s latest transaction?
David Andrew Posner’s latest transaction was an Uninformative Sell of C$40.00K.
What was David Andrew Posner's most profitable transaction?
David Andrew Posner’s most profitable transaction was an Informative Buy of TSE:MJMJ stock on October 12, 2016. The return on the trade was 24.10%.
What is David Andrew Posner's role in Pharmadrug?
David Andrew Posner's role in Pharmadrug is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.